Oral administration of a stable analog of prostaglandin El (PGE,), 15-(S)-15-methyl-prostaglandin
It is becoming increasingly evident that prostaglandins (PG) play an integral role in regulating the functions of cells involved in immune and inflammatory reactions (1) . Clearly not only are PG produced by inflammatory cells and able to influence the outcome of inflammation (2) , but they can also suppress diverse effector systems in inflammatory reactions. Thus, PGE compounds, which increase levels of cyclic AMP in leukocytes, reduce chemotactic responses of polymorphonuclear leukocytes (PMN) (3), reduce selective extrusion of IysosomaI enzymes from PMN (4), prevent IgE-induced histamine release from lung fragments and basophils (5) , and inhibit lymphocyte mediated cytotoxicity (6) . Pharmacologic doses of PGE, and PGE, administered subcutaneously suppress both acute and chronic inflammation in several experimental models (7) . Furthermore, PGE have been shown to modulate the effects of vasoactive compounds (8), which are responsible for many early changes in both acute and chronic immune reactions.
Prostaglandin E compounds appear to have a regulatory effect on the character and intensity of immune responses in vivo (9) . Long-term administration of PGE, has proved feasible and has been shown to markedly prolong survival of NZB/NZW (lupus) mice, even when treatment is begun after nephritis has developed (10) . However, under these conditions, the dose of PGE, required is substantial (200 pg subcutaneously, twice daily). A derivative of PGE,-l5-(S)-15-methyl PGE,( 1 5-M-PGEIehas been developed and is more resistant than PGE, to the activity of 1 S-hydroxy-prostaglandin dehydrogenase (1 1). Previously, we have reported (12) that a very small dose of I5-M-PGEI (4 pg given subcutaneously, twice daily) prolongs survival of NZB/NZW mice in which there is established disease at the time treatment is begun. In addition, we have reported ( 13) that immune complex-induced vascular damage can be markedly suppressed by treatment of rats with l5-M-PGEI.
We now show that oral administration of 15-M-PGE, in a dose dependent manner suppresses acute immune complex-induced vasculitis and adjuvant-induced chronic polyarthritis in rats. The reversed passive Arthus reaction (RPA) is induced by the intravenous administration of antigen and the local (intradermal) injection of antibody and is a good model for immunologically induced acute vasculitis. Adjuvant arthritis appears in rats 10-14 days after a single intradermal injection of Freund's complete adjuvant and is a good model for chronic inflammation that is dependent on cell mediated immunity; thus, adjuvant arthritis provides a convenient experimental model for in vivo evaluation of antiinflammatory and/or immunosuppressive agents (14) . This work to be reported here represents one of the first efforts to regulate both acute and chronic inflammatory reactions in animal models by oral treatment with PG.
MATERIALS AND METHODS
Animals. Adult male Lewis rats (Charles River Breeding Laboratories, Wilmington, MA) weighing 200-250 gm were used throughout these studies.
Adjuvant-induced chronic arthritis. Polyarthritis was induced in the Lewis rat by the intradermal injection of 500 p g heat-killed Mycobocferiurn tuberculosis organisms (Difco Laboratories, Detroit, MI) in 0.1 ml of mineral oil into the left hind paw. Adjuvant-induced arthritis appeared in all positive control rats at approximately day 14. The severity of the polyarthritis was evaluated in the 3 uninjected paws by using both an arbitrary point system and direct measurement with a caliper. The uninjected paws were scored in the following manner: 1 point was assigned for each of the inflamed tibiotarsal joints, 5 points for each of the inflamed tarsal joints, and 5 points for arthritic involvement of the tail. Each of 4 groups containing 10 rats each were injected with the M tuberculosis in oil and were separated into Group 1, which received 200 p g of IS-M-PGE, once daily from the day of adjuvant challenge; Group 2, which received 100 pg of 15-M-PGE, by mouth from the day of adjuvant injection; Group 3, which received 50 pg of lS-M-PGE, once daily again from the time of adjuvant injection; and Group 4, which was given 0.5 ml of fluid. All of the above experiments were conducted in triplicate on three different occasions. The progress of the polyarthritic joint disease was also followed in the noninjected paws by measuring each of the joints with a caliper at 2-day intervals.
Immune complex-induced acute vasculitis. The reversed passive Arthus reaction using rabbit IgG antibody to bovine serum albumin (BSA) was used as the antibody to elicit the immune complex vasculitis, as previously described (15) . Approximately 150 p1 of anti-BSA IgG containing 150 pg N antibody was injected intradermally, followed by the intravenous injection of 10 mg BSA and I pCi of I2'I rat serum albumin. The radiolabeled rat serum albumin served as a permeability marker and as an index for the degree of vascular damage (16) . Negative control sites were injected with saline or antibody from which the intravenous injection of antigen was omitted. Three hours after antigen-antibody challenge, the animals were killed. At the site of each intradermal injection, a circular punch of skin 1 cm in diameter was excised. In addition, 1 ml of blood was removed from the left ventricle of the heart; both skin and blood samples were measured for gamma emissions. The ratio of radioactivity in each skin site/ 1 ml of blood was computed and used as the permeability index.
Prostaglandins. Prostaglandins were a gift of Dr. John E. Pike, Upjohn Co., Kalamazoo, Michigan. Stock solutions of PG12, lS-M-PGE,, and 16,16 dimethyl PGE, were prepared in absolute ethanol and diluted to 10 mg/ml in sterile phosphate buffered saline (PBS), pH 7.2. Prior to use, the PG were diluted to the desired concentration with PBS.
Morphologic analysis. Skin samples from the various inflammatory and control sites were fixed in phosphate buffered @H 7.0) 10% formaldehyde and were then prepared for routine light microscopy. After killing the animals with ether anesthesia, the legs of all those challenged with the Mycobacterium in mineral oil were removed and k e d in buffered 10%0 formaldehyde and then decalcified with acetic acid. Sections of each fixed and decalcified tibiotarsal joint were stained with hematoxylin and eosin.
Statistical analysis. The unpaired Student's f-test was used to analyze the data.
RESULTS
Suppression of polyarthritis by oral prostaglandin treatment. A severe polyarthritic response was grossly visible in all non-PG treated control rats. Using oral treatment with 15-M-PGE,, a dose dependent amelioration of the polyarthritis was observed. Little or no gross change was observed in the joints of animals given 200 pg of the 15-M-PGEl daily from the time of adjuvant administration. The oral administration of 100 pg and 50 pg of 15-M-PGE, resulted in a significant gross attenuation of the polyarthritis as compared to the control animals. Prostaglandin treatment of rats with 200 pg l5-M-PGEI led to diarrhea and somnolence which lasted approximately 1 hour, while the lower doses produced only transient diarrhea and the animals remained active.
As shown in Figure 1 , oral administration of 15-M-PGE, markedly suppressed the polyarthritic response in a dose-dependent manner. The oral administration of 200 pg 15-M-PGE, resulted in a 90% reduction in the mean arthritic score of the joints in the non-adjuvant treated paws by day 20. It is interesting to note that not only was the degree of swelling of the soft tissue around the joints markedly diminished in the ani- Although not as dramatic as with the higher dose, the daily oral administration of 100 pg and 50 pg of 15-M-PGE, suppressed the polyarthritis by 500/0 and 20%, respectively ( Figure 1 ). In both PG treated and nontreated animals, the peak arthritic response occurred at approximately day 21. As compared to nontreated rats, the mean paw thickness in all the 15-M-PGE, treated animals was significantly reduced, indicative of a suppression of soft tissue swelling in each of the joints. As shown in Table 1 , the mean paw thickness measured at day 20 following adjuvant injection was suppressed in a dose-dependent manner. There was little statistical difference between the mean paw thickness in the 200 pg 15-M-PGE, treated animals (injected with adjuvant) and normal (non-adjuvant treated) control animals. Although not as dramatic as with the 200 pg dose, the oral administration of 100 pg and 50 pg attenuated the joint swelling in each of the noninjected paws. It is also of interest that the swelling of soft tissue in the adjuvant-injected left hind paw was suppressed in a dose-dependent fashion.
Histology of tibiotarsal joints from treated and untreated rats 20 days after adjuvant injection was compared with joints from normal rats. A histologic section from a joint of an animal with polyarthritis is shown in Figure 2 . The histologic changes evident in polyarthritic rats demonstrated significant encroachment of the joint space by an inflamed synovium and advancement of pannus to the center of the cartilage. The inflammatory response associated with erosion of articular cartilage was characteristic of fully developed adjuvant arthritis (Figure 2) . Arthritis failed to develop in joints of rats treated (from day 1) with 200 pg of 15-M-PGEI; histologically, these joints appeared normal. Joints from animals treated with 100 pg 15-M-PGEl demonstrated extension of pannus only over the periphery of cartilage. Also, invasion of cartilage and bone by pannus was seen in joints of animals treated with 50 pg/day 15-M-PGEl, but the joint space was preserved (Figure 3 ), demonstrating the dose response of PGE treatment. These results indicate that the arthritic reaction in animals treated orally with 15-M-PGEl are either attenuated (100 or 50 pg) or totally suppressed (200 pg) in a manner that is dose-dependent.
Suppression of acute vasculitis. Oral administration of 15-M-PGE, suppressed acute immune complexinduced vasculitis in a dose-dependent manner ( Figure  4) . In this particular study, animals were treated 12 hours previously with the 15-M-PGEl and then injected with antigen and antibody. Changes in the vascular permeability indicative of the intensity of the inflammatory reaction and tissue injury were always related to values found in saline injected sites. Animals serving as positive controls received the intradermal injections of antibody and intravenous injection of BSA plus labeled rat albumin, but they were not treated with PG. For each Table 1 PGE, treatment of rats resulted in suppression of vascular damage ranging from approximately 10% at the dose of 50 pg 15-M-PGEl to 75% suppression with the 250 pg dose (Figure 4) . In an attempt to determine whether the long lasting suppression of immune compIex vasculitis could only be induced by treatment with the 15-methyl derivative of PGE,, both PGI,, and a PGE, analog with a dimethyl at the 16 position were also studied. Oral administration of either PGI,, PGE,, or 16,16 dimethyl PGE, did not suppress acute vasculitis. However, since subcutaneous injections of PGE, suppress immune complex vasculitis (13) , animals were treated subcutaneously with either PGI, or 16,16 dimethyl PGE,, rested for 1 hour, and then challenged with antigen and antibody. The largest dose of the administered PGI, (500 pg) resulted in a reduction of vascular permeability by approximately 50%, while 250 pg PGI, caused a diminution of the vascular leakage by 10% ( Figure 5 ). The treatment of animals with 500 pg 16,16 dimethyl PGE,, in the manner as described for PGI,, resulted in a suppression of the vascular leakage by 6Wo. When 250 pg of this PGE, analog was examined, the permeability was reduced by 35% ( Figure 6 ).
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In all positive control reactions, the skin lesions were shown to have extensive deposition of both BSA and C3 in walls of dermal venules and capillaries, as determined by immunofluorescence. In rats treated with 15-M-PGEi, the deposition of BSA and C3 were confined mainly to the immediately adjacent perivascular tissue. Thus, it appeared that PG treatment did not block complement fixation or deposition of immune complexes. When vascular damage was suppressed by the prostaglandin treatment, skin reactions were visibly inhibited, with little induration, edema, or erythema. Histologically, the nontreated positive sites showed the expected diffuse intraluminal, perivascular infiltrates of polymorphonuclear leukocytes ( Figure 6A ). In contrast, lesions from rats treated with a suppressive dose of either PG showed a diminished infiltrate of neutrophils ( Figure 6B ). The histology of the PG-suppressed lesions appeared similar, and the intensity of the reactions was dose-dependent.
DISCUSSION
The data presented in this paper indicate that oral administration of a stable derivative of PGE,, 15(S)-15-methyl PGE,, produces potent suppression of acute immune complex-induced inflammatory reactions, as well as suppression of the more delayed and chronic inflammatory response in adjuvant arthritis.
The suppressive effect of oral 15-M-PGEl treatment appears to be partially specific since no inhlbition of the inflammatory response occurred with oral administration of 16,16 dimethyl PGE, or PGI,. This reflects both the enzymatic and spontaneous degradation of these two compounds, especially PGI,. The ability to inhibit the arthritic response by oral treatment of therapeutic levels of 15-M-PGEl probably lies in the molecular structure of the analog, which is not susceptible to the 15-hydroxy-prostaglandin dehydrogenase (1 1). The activity of this enzyme is probably the reason why significant doses of the classic prostaglandins are required to achieve physiologic effects (17) .
The pathogenesis of the Arthus reaction may not be dissimilar from the series of events thought to be responsible for joint tissue damage in rheumatoid arthritis ( response to chemotactic products, endocytosis of immune complexes, and subsequent release of lysosomal enzymes and other mediators of inflammation resulting in vascular damage (1 8) . Previous investigations have shown that treatment of rats with ISM-PGE, can modulate many of the above steps in the acute inflammatory response, especially the direct motion and degranulation of peripheral blood neutrophils (13) . The ability of both the classic prostaglandin E, and prostacyclin to inhibit immune complex-induced vasculitis may be due to the interaction of these particular prostaglandins with identical receptors on the neutrophil surface. Previous investigators (19) have proposed that prostaglandins of the E series and prostacyclin bind to similar granulocyte receptors to induce an increase in intracellular cyclic AMP levels, thus leading to an attenuation of inflammatory responses. The ability of PGE, and PGI, to bind identical receptors and inhibit adenosine diphosphate-induced aggregation of platelets in a number of species has also been established (20) . Therefore the effects of PGE, and PGI, on neutrophil dependent, immune complex-induced vasculitis may add credence to the identical binding theory of these two prostaglandins.
Whereas acute immune complex-induced vasculitis is characterized by neutrophil infiltration, tissue proliferation is the hallmark of chronic inflammation. Therefore, appropriate control of cell proliferation is crucial to improved management of a disease like RA, for example, in which synovium develops into granulation tissue (pannus) that invades and erodes articular cartilage. Intracellular degradation of newly synthesized collagen in vitro is inhibited by PGE (21) , and this action may aid in the control of collagen deposition in chronic inflammatory disorders.
The role of prostaglandins in immunologic responses and inflammatory reactions is complex, but these ubiquitous compounds do appear important in the regulation of cell function and host defenses. Studies such as those presented here do not necessarily argue for a physiologic role for prostaglandins. They do suggest that pharmacologic doses of prostaglandins, even when given by mouth, may be capable of influencing some aspects of immunity and inflammation and can prevent tissue injury. That PGE can inhibit the dermal Arthus reaction makes it not unreasonable to consider its use in treatment of cutaneous vasculitis not controlled by more traditional therapy.
The therapeutic potential of the prostaglandins appears great, and their use for a wide variety of diseases is just beginning. Whether they will prove helpful clinically as modulators of immune/inflammatory responses is not yet clear.
